Abstract: The present invention relates to a recombinant polypeptide comprising a LytM catalytic domain, and a lysostaphin cell wall binding domain, optionally, an amino acid linker, and, optionally, a domain directing to the inside of an eukaryotic cell, for use as a medicine, antiseptic agent, antibacterial agent and/or anti-inflammatory agent. In particular, the invention relates to a recombinant polypeptide for use in the prevention and/or treatment of a dermatological disorder and/or inflammation. The recombinant polypeptide formulated for topical administration is also encompassed. A veterinary composition for intramammary administration comprising the recombinant polypeptide, in particular, for use in the treatment of mastitis, is also included. The invention also relates to the use of the recombinant polypeptide as a diagnostic reagent, disinfectant, antiseptic and antibacterial agent, as well as a pharmaceutical, cosmetic or care composition comprising thereof.

Abstract: The present invention relates to a method for selection or screening of hDIS3 PIN domain inhibitors, yeast strain and cell line used in such methods It also relates to new therapeutic agents selected hDIS3 PIN domain inhibitors and uses thereof in the treatment of cancers having mutations inhDIS3 RNB domain, especially multiple myeloma. The invention also relates to composition comprising new therapeutic agent hDIS3 PIN domain inhibitor and method for inducing synthetic lethality in a cancer cell.